In last trading session, TransCode Therapeutics Inc (NASDAQ:RNAZ) saw 10.31 million shares changing hands with its beta currently measuring 1.36. Company’s recent per share price level of $0.74 trading at -$0.28 or -27.25% at ring of the bell on the day assigns it a market valuation of $0.52M. That closing price of RNAZ’s stock is at a discount of -8863.51% from its 52-week high price of $66.33 and is indicating a discount of -31.08% from its 52-week low price of $0.97. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.98 million shares which gives us an average trading volume of 2.09 million if we extend that period to 3-months.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
Upright in the red during last session for losing -27.25%, in the last five days RNAZ remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $0.74 price level, adding 55.95% to its value on the day. TransCode Therapeutics Inc’s shares saw a change of -77.98% in year-to-date performance and have moved -56.09% in past 5-day. TransCode Therapeutics Inc (NASDAQ:RNAZ) showed a performance of -93.15% in past 30-days. Number of shares sold short was 0.54 million shares which calculate 0.16 days to cover the short interests.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 300k for the same.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -28.81% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 95.41% while estimates for its earnings growth in next 5 years are of 78.85%.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Insiders are in possession of 0.01% of company’s total shares while institution are holding 22.36 percent of that, with stock having share float percentage of 22.37%. Investors also watch the number of corporate investors in a company very closely, which is 22.36% institutions for TransCode Therapeutics Inc that are currently holding shares of the company.
On the other hand, Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.86 shares of worth $2125.0 or 0.41% of the total outstanding shares. The later fund manager was in possession of 1.18 shares on Dec 31, 2024 , making its stake of worth around $874.0 in the company or a holder of 0.17% of company’s stock.
